Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Heron Therapeutics Inc (NASDAQ:HRTX)

20.62
Delayed Data
As of 1:14pm ET
 +0.088 / +0.43%
Today’s Change
11.54
Today|||52-Week Range
42.25
-22.78%
Year-to-Date
Heron and the Never-Ending FDA Drug Review
May 18 / TheStreet.com - Paid Partner Content
Here's Why Trevena Stock Dropped 18% Today
May 16 / MotleyFool.com - Paid Partner Content
Heron and the Never-Ending FDA Drug Review
May 18 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close20.53
Today’s open20.74
Day’s range20.15 - 21.09
Volume196,912
Average volume (3 months)700,858
Market cap$752.6M
Dividend yield--
Data as of 1:14pm ET, 05/25/2016

Growth & Valuation

Earnings growth (last year)-2.79%
Earnings growth (this year)-16.84%
Earnings growth (next 5 years)+54.07%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book6.28

Competitors

 Today’s
change
Today’s
% change
EGRXEagle Pharmaceutical...-0.45-0.91%
INSMInsmed Inc+0.11+0.93%
CPXXCelator Pharmaceutic...+0.33+1.93%
ADROAduro Biotech Inc+0.21+1.92%
Data as of 1:29pm ET, 05/25/2016

Financials

Next reporting dateAugust 8, 2016
EPS forecast (this quarter)-$0.89
Annual revenue (last year)$0.00
Annual profit (last year)-$97.6M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Barry D. Quart
President, Director &
Chief Commercial Officer
Robert H. Rosen
Corporate headquarters
Redwood City, California

Forecasts

Partner Offers

Search for Jobs